马拉维农村新诊断HIV成人中Xpert MTB/RIF检测与荧光显微镜筛查结核的整群随机试验(Chepetsa)
在马拉维Thyolo农村12家初级卫生诊所开展整群随机试验,新诊断HIV成人按诊所1:1分配至即时Xpert MTB/RIF或即时LED荧光显微镜筛查结核,有症状者接受检测、无症状者两组均获异烟肼预防治疗。Xpert组12个月全因死亡率降低22%(6.7 vs 8.6/100人年;RR 0.78,95%CI 0.58-1.06),计划亚组分析中WHO临床3或4期患者死亡率更低(RR 0.43,95%CI 0.22-0.87)。
要点
- Xpert组检出结核24/1001(2.4%),LED-FM组10/841(1.2%)。
- Xpert组12个月全因死亡率为6.7/100人年,LED-FM组为8.6/100人年。
- WHO临床3或4期患者中Xpert组死亡率低于LED-FM组(RR 0.43,95%CI 0.22-0.87)。
核心结论
- 在马拉维农村,HIV诊断时对症状阳性患者使用即时Xpert MTB/RIF检测结核降低了晚期HIV患者的12个月全因死亡率。
研究设计与样本
- 在马拉维Thyolo农村12家初级卫生诊所开展整群随机试验,诊所按1:1分配至即时Xpert MTB/RIF或即时LED荧光显微镜筛查。
- 研究对象为新诊断HIV成人,有结核症状者接受相应检测,无症状者两组均接受异烟肼预防治疗。
- 研究者对分组设盲,诊所工作人员和参与者未设盲;主要结局为HIV诊断后12个月内全因死亡率的率比(RR)。
主要发现
- Xpert组检出结核24/1001(2.4%),LED-FM组检出结核10/841(1.2%)。
- Xpert组12个月全因死亡率为6.7/100人年,LED-FM组为8.6/100人年,Xpert组较LED-FM组降低22%(RR 0.78,95%CI 0.58-1.06)。
- 计划亚组分析显示WHO临床3或4期患者中Xpert组死亡率低于LED-FM组(RR 0.43,95%CI 0.22-0.87)。
关键数值与推荐
- 主要结局:12个月全因死亡率RR 0.78(95%CI 0.58-1.06),Xpert组6.7/100人年 vs LED-FM组8.6/100人年。
- WHO临床3或4期亚组:RR 0.43(95%CI 0.22-0.87),Xpert组低于LED-FM组。
临床怎么用
- 原文结论为在马拉维农村HIV诊断时使用即时Xpert MTB/RIF检测有症状患者结核降低了晚期HIV患者的12个月全因死亡率。
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) remains the leading cause of death among human immunodeficiency virus (HIV)-infected individuals globally. Screening for TB at the point of HIV diagnosis with a high-sensitivity assay presents an opportunity to reduce mortality. METHODS: We performed a cluster randomized trial of TB screening among adults newly diagnosed with HIV in 12 primary health clinics in rural Thyolo, Malawi. Clinics were allocated in a 1:1 ratio to perform either point-of-care Xpert MTB/RIF assay (Xpert) or point-of-care light-emitting diode fluorescence microscopy (LED-FM) for individuals screening positive for TB symptoms. Asymptomatic participants were offered isoniazid preventive therapy in both arms. Investigators, but not clinic staff or participants, were masked to allocation. Our primary outcome was the incidence rate ratio (RR) of all-cause mortality within 12 months of HIV diagnosis. RESULTS: Prevalent TB was diagnosed in 24 of 1001 (2.4%) individuals enrolled in clinics randomized to Xpert, compared with 10 of 841 (1.2%) in clinics randomized to LED-FM. All-cause mortality was 22% lower in the Xpert arm than in the LED-FM arm (6.7 vs 8.6 per 100 person-years; RR, 0.78 [95% confidence interval {CI}, .58-1.06]). A planned subgroup analysis suggested that participants with more advanced HIV (World Health Organization clinical stage 3 or 4) disease had lower mortality in clinics randomized to Xpert than to LED-FM (RR, 0.43 [95% CI, .22-.87]). CONCLUSIONS: In rural Malawi, using point-of-care Xpert MTB/RIF to test symptomatic patients for TB at the time of HIV diagnosis reduced all-cause 12-month mortality among individuals with advanced HIV. CLINICAL TRIALS REGISTRATION: NCT01450085.
引用
- Ngwira LG, Corbett EL, Khundi M, et al. Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa). Clin Infect Dis. 2019. PMID: 30059995. doi:10.1093/cid/ciy590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。